{"id":437091,"date":"2025-03-07T14:38:55","date_gmt":"2025-03-07T17:38:55","guid":{"rendered":"https:\/\/mrnews.com.br\/?p=437091"},"modified":"2025-03-07T14:40:10","modified_gmt":"2025-03-07T17:40:10","slug":"anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil","status":"publish","type":"post","link":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/","title":{"rendered":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil"},"content":{"rendered":"

Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil<\/strong><\/p>\n

S\u00e3o Paulo, 7 de mar\u00e7o de 2025<\/em> \u2013 A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa<\/a>) aprovou, nesta sexta-feira, 7 de mar\u00e7o, o Awiqli\u00ae (insulina basal icodeca), tornando-o a primeira insulina de aplica\u00e7\u00e3o semanal dispon\u00edvel no pa\u00eds para o tratamento de pacientes adultos com diabetes tipo 1 e 2. Desenvolvido pela Novo Nordisk, o Awiqli\u00ae representa um avan\u00e7o significativo no manejo do diabetes, permitindo aos pacientes reduzir de sete para uma o n\u00famero de aplica\u00e7\u00f5es de insulina por semana, sem comprometer o controle glic\u00eamico.<\/p>\n

Fonte abcdmaior.com.br<\/a><\/p>\n

Efic\u00e1cia e Seguran\u00e7a Comprovadas<\/strong><\/p>\n

A aprova\u00e7\u00e3o do Awiqli\u00ae baseou-se em extensos estudos cl\u00ednicos que demonstraram sua efic\u00e1cia no controle dos n\u00edveis de glicose. No caso do diabetes tipo 1, os pacientes que utilizaram o Awiqli\u00ae mantiveram n\u00edveis adequados de glicemia ao longo da semana com uma \u00fanica inje\u00e7\u00e3o semanal, alcan\u00e7ando controle glic\u00eamico compar\u00e1vel ao das insulinas basais de aplica\u00e7\u00e3o di\u00e1ria. Para pacientes com diabetes tipo 2, o Awiqli\u00ae tamb\u00e9m mostrou efic\u00e1cia semelhante, proporcionando um controle glic\u00eamico eficaz e est\u00e1vel, com um perfil de seguran\u00e7a favor\u00e1vel, sem aumento significativo de eventos adversos graves, incluindo hipoglicemia.<\/p>\n

Impacto no Tratamento do Diabetes<\/strong><\/p>\n

A introdu\u00e7\u00e3o do Awiqli\u00ae no mercado brasileiro representa uma mudan\u00e7a de paradigma no tratamento do diabetes. Com uma \u00fanica aplica\u00e7\u00e3o semanal, os pacientes podem alcan\u00e7ar um controle glic\u00eamico eficaz, simplificando o regime de tratamento e potencialmente melhorando a ades\u00e3o ao mesmo. Al\u00e9m disso, a redu\u00e7\u00e3o no n\u00famero de inje\u00e7\u00f5es pode contribuir para uma melhor qualidade de vida, diminuindo o desconforto associado \u00e0s aplica\u00e7\u00f5es di\u00e1rias.<\/p>\n

Disponibilidade e Acompanhamento M\u00e9dico<\/strong><\/p>\n

Embora o Awiqli<\/a>\u00ae tenha recebido aprova\u00e7\u00e3o da Anvisa, ainda n\u00e3o h\u00e1 uma data definida para o seu lan\u00e7amento no mercado brasileiro. A Novo Nordisk aguarda a defini\u00e7\u00e3o de pre\u00e7os pela C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos (CMED) para estabelecer a data de disponibilidade do produto. Enquanto isso, os pacientes interessados devem consultar seus m\u00e9dicos para obter informa\u00e7\u00f5es detalhadas sobre o tratamento e discutir a adequa\u00e7\u00e3o do Awiqli\u00ae \u00e0s suas necessidades espec\u00edficas.<\/p>\n

A aprova\u00e7\u00e3o do Awiqli\u00ae refor\u00e7a o compromisso da Novo Nordisk em oferecer solu\u00e7\u00f5es inovadoras no tratamento do diabetes, alinhando-se \u00e0 sua miss\u00e3o de derrotar doen\u00e7as cr\u00f4nicas graves por meio de investimentos cont\u00ednuos em pesquisa e desenvolvimento.<\/p>\n","protected":false},"excerpt":{"rendered":"

Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil S\u00e3o Paulo, 7 de mar\u00e7o de 2025 \u2013 A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta sexta-feira, 7 de mar\u00e7o, o Awiqli\u00ae (insulina basal icodeca), tornando-o a primeira insulina de aplica\u00e7\u00e3o semanal dispon\u00edvel no pa\u00eds para o tratamento …<\/p>\n","protected":false},"author":1,"featured_media":322047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[12225,4],"tags":[],"class_list":["post-437091","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","category-servicos"],"yoast_head":"\nAnvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil\" \/>\n<meta property=\"og:description\" content=\"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil S\u00e3o Paulo, 7 de mar\u00e7o de 2025 \u2013 A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta sexta-feira, 7 de mar\u00e7o, o Awiqli\u00ae (insulina basal icodeca), tornando-o a primeira insulina de aplica\u00e7\u00e3o semanal dispon\u00edvel no pa\u00eds para o tratamento …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/\" \/>\n<meta property=\"og:site_name\" content=\"MRNews\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/eaipahpah\/?locale2=pt_BR\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-07T17:38:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-07T17:40:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png\" \/>\n\t<meta property=\"og:image:width\" content=\"250\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MR News\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@conspirou\" \/>\n<meta name=\"twitter:site\" content=\"@conspirou\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"MR News\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/\"},\"author\":{\"name\":\"MR News\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#\\\/schema\\\/person\\\/be3203154562a9f207407861cef7827b\"},\"headline\":\"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil\",\"datePublished\":\"2025-03-07T17:38:55+00:00\",\"dateModified\":\"2025-03-07T17:40:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mrnews.com.br\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/google-news-siga-nos-7.png\",\"articleSection\":[\"NOTICIAS\",\"SERVI\u00c7OS\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/\",\"url\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/\",\"name\":\"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mrnews.com.br\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/google-news-siga-nos-7.png\",\"datePublished\":\"2025-03-07T17:38:55+00:00\",\"dateModified\":\"2025-03-07T17:40:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mrnews.com.br\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/google-news-siga-nos-7.png\",\"contentUrl\":\"https:\\\/\\\/mrnews.com.br\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/google-news-siga-nos-7.png\",\"width\":250,\"height\":200,\"caption\":\"google news siga nos\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/2025\\\/03\\\/07\\\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/mrnews.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#website\",\"url\":\"https:\\\/\\\/mrnews.com.br\\\/\",\"name\":\"MRNews\",\"description\":\"MRNews Jogos de hoje da TV, transmiss\u00f5es ao vivo, Not\u00edcias de futebol, Jogos ao vivo, Lives, resumo de novelas, Programa\u00e7\u00e3o da Globo, A Fazenda e BBB\",\"publisher\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mrnews.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#organization\",\"name\":\"MRNews\",\"url\":\"https:\\\/\\\/mrnews.com.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mrnews.com.br\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/MRNewslogo2.png\",\"contentUrl\":\"https:\\\/\\\/mrnews.com.br\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/MRNewslogo2.png\",\"width\":223,\"height\":58,\"caption\":\"MRNews\"},\"image\":{\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/eaipahpah\\\/?locale2=pt_BR\",\"https:\\\/\\\/x.com\\\/conspirou\",\"https:\\\/\\\/www.instagram.com\\\/eai_pahpah\",\"https:\\\/\\\/br.pinterest.com\\\/mrnewsn\\\/boards\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCacgnpznQ61fifLWr1tQ-vA?view_as=subscriber\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mrnews.com.br\\\/#\\\/schema\\\/person\\\/be3203154562a9f207407861cef7827b\",\"name\":\"MR News\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/04084e6d73c042b8646e7c17b494073bf0ede3ea13c7105cfc45cbbbc28385a4?s=96&d=monsterid&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/04084e6d73c042b8646e7c17b494073bf0ede3ea13c7105cfc45cbbbc28385a4?s=96&d=monsterid&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/04084e6d73c042b8646e7c17b494073bf0ede3ea13c7105cfc45cbbbc28385a4?s=96&d=monsterid&r=g\",\"caption\":\"MR News\"},\"description\":\"Especializado em jornalismo colaborativo pela FTP em n\u00edvel de p\u00f3s-gradua\u00e7\u00e3o. suporte@oimeliga.combr\",\"sameAs\":[\"HUGO R.\",\"Admin\"],\"url\":\"https:\\\/\\\/mrnews.com.br\\\/index.php\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil","og_description":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil S\u00e3o Paulo, 7 de mar\u00e7o de 2025 \u2013 A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta sexta-feira, 7 de mar\u00e7o, o Awiqli\u00ae (insulina basal icodeca), tornando-o a primeira insulina de aplica\u00e7\u00e3o semanal dispon\u00edvel no pa\u00eds para o tratamento …","og_url":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/","og_site_name":"MRNews","article_publisher":"https:\/\/www.facebook.com\/eaipahpah\/?locale2=pt_BR","article_published_time":"2025-03-07T17:38:55+00:00","article_modified_time":"2025-03-07T17:40:10+00:00","og_image":[{"width":250,"height":200,"url":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png","type":"image\/png"}],"author":"MR News","twitter_card":"summary_large_image","twitter_creator":"@conspirou","twitter_site":"@conspirou","twitter_misc":{"Escrito por":"MR News","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#article","isPartOf":{"@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/"},"author":{"name":"MR News","@id":"https:\/\/mrnews.com.br\/#\/schema\/person\/be3203154562a9f207407861cef7827b"},"headline":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil","datePublished":"2025-03-07T17:38:55+00:00","dateModified":"2025-03-07T17:40:10+00:00","mainEntityOfPage":{"@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/mrnews.com.br\/#organization"},"image":{"@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#primaryimage"},"thumbnailUrl":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png","articleSection":["NOTICIAS","SERVI\u00c7OS"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/","url":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/","name":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil","isPartOf":{"@id":"https:\/\/mrnews.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#primaryimage"},"image":{"@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#primaryimage"},"thumbnailUrl":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png","datePublished":"2025-03-07T17:38:55+00:00","dateModified":"2025-03-07T17:40:10+00:00","breadcrumb":{"@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#primaryimage","url":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png","contentUrl":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png","width":250,"height":200,"caption":"google news siga nos"},{"@type":"BreadcrumbList","@id":"https:\/\/mrnews.com.br\/index.php\/2025\/03\/07\/anvisa-aprova-awiqli-primeira-insulina-semanal-para-tratamento-de-diabetes-tipo-1-e-2-no-brasil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/mrnews.com.br\/"},{"@type":"ListItem","position":2,"name":"Anvisa Aprova Awiqli\u00ae: Primeira Insulina Semanal para Tratamento de Diabetes Tipo 1 e 2 no Brasil"}]},{"@type":"WebSite","@id":"https:\/\/mrnews.com.br\/#website","url":"https:\/\/mrnews.com.br\/","name":"MRNews","description":"MRNews Jogos de hoje da TV, transmiss\u00f5es ao vivo, Not\u00edcias de futebol, Jogos ao vivo, Lives, resumo de novelas, Programa\u00e7\u00e3o da Globo, A Fazenda e BBB","publisher":{"@id":"https:\/\/mrnews.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mrnews.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/mrnews.com.br\/#organization","name":"MRNews","url":"https:\/\/mrnews.com.br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mrnews.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2019\/06\/MRNewslogo2.png","contentUrl":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2019\/06\/MRNewslogo2.png","width":223,"height":58,"caption":"MRNews"},"image":{"@id":"https:\/\/mrnews.com.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/eaipahpah\/?locale2=pt_BR","https:\/\/x.com\/conspirou","https:\/\/www.instagram.com\/eai_pahpah","https:\/\/br.pinterest.com\/mrnewsn\/boards\/","https:\/\/www.youtube.com\/channel\/UCacgnpznQ61fifLWr1tQ-vA?view_as=subscriber"]},{"@type":"Person","@id":"https:\/\/mrnews.com.br\/#\/schema\/person\/be3203154562a9f207407861cef7827b","name":"MR News","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/04084e6d73c042b8646e7c17b494073bf0ede3ea13c7105cfc45cbbbc28385a4?s=96&d=monsterid&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/04084e6d73c042b8646e7c17b494073bf0ede3ea13c7105cfc45cbbbc28385a4?s=96&d=monsterid&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/04084e6d73c042b8646e7c17b494073bf0ede3ea13c7105cfc45cbbbc28385a4?s=96&d=monsterid&r=g","caption":"MR News"},"description":"Especializado em jornalismo colaborativo pela FTP em n\u00edvel de p\u00f3s-gradua\u00e7\u00e3o. suporte@oimeliga.combr","sameAs":["HUGO R.","Admin"],"url":"https:\/\/mrnews.com.br\/index.php\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/mrnews.com.br\/wp-content\/uploads\/2022\/01\/google-news-siga-nos-7.png","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pa2Qf7-1PHR","amp_enabled":true,"_links":{"self":[{"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/posts\/437091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/comments?post=437091"}],"version-history":[{"count":1,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/posts\/437091\/revisions"}],"predecessor-version":[{"id":437094,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/posts\/437091\/revisions\/437094"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/media\/322047"}],"wp:attachment":[{"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/media?parent=437091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/categories?post=437091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mrnews.com.br\/index.php\/wp-json\/wp\/v2\/tags?post=437091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}